CG Oncology enters amended employment agreements with CEO, President, and three other executives with enhanced severance

CG Oncology, Inc.

CEO Arthur Kuan and President/COO Ambaw Bellete: 1.5x salary + prorated bonus outside CIC; 2.0x salary + full bonus inside CIC.
COBRA premium payments for up to 18 months (CIC: 24 months) and 18-month equity acceleration (CIC: full vesting).
Bellete's June 2023 option of 432,311 shares gets full accelerated vesting after second anniversary on termination without cause outside CIC.
CMO Kasturi, CFO Roche, GC Patterson: 1.0x salary + 12-month COBRA outside CIC; 1.5x salary + 18-month COBRA inside CIC.
All agreements dated January 9, 2025; full text to be filed in 2024 Form 10-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.